Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 16/20 | 0.42 |
| ▸ | KRAS | P01116 | 5/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844200 | 1.00 | SOS1 (0.42) | SOS1KRASTRPV4ELANERAF1 | |
| SCHEMBL27186252 | 1.00 | SOS1 (0.42) | SOS1KRASTRPV4ELANERAF1 | |
| SCHEMBL27186112 | 0.85 | SOS1 (0.42) | SOS1KRASTRPV4ELANERAF1 | |
| SCHEMBL27186120 | 0.85 | SOS1 (0.42) | SOS1KRASTRPV4ELANERAF1 | |
| SCHEMBL29844219 | 0.85 | SOS1 (0.42) | SOS1KRASTRPV4ELANERAF1 | |
| SCHEMBL27186093 | 0.83 | SOS1 (0.39) | SOS1KRASTRPV4ELANERAF1 | |
| SCHEMBL29844166 | 0.83 | SOS1 (0.39) | SOS1KRASTRPV4ELANERAF1 | |
| SCHEMBL27186095 | 0.83 | SOS1 (0.39) | SOS1KRASTRPV4ELANERAF1 | |
| SCHEMBL27186885 | 0.77 | KRAS (0.40) | SOS1KRAS | |
| SCHEMBL27186887 | 0.77 | KRAS (0.40) | SOS1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | SOS1 1/4885KRAS 10/4885TRPV4 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.